摘要
目的对国产注射用头孢哌酮钠舒巴坦钠的质量现状进行评价。方法按中国药典及有关标准进行检验,利用统计手段分析检验结果。结果30个企业生产的54批注射用头孢哌酮舒巴坦钠中,17批不合格,占31.5%,涉及10个厂家。不合格项目主要是溶液的澄清度和头孢哌酮的纯度。结论目前国产注射用头孢哌酮钠舒巴坦钠存在的主要质量问题是头孢哌酮的稳定性和溶液的澄清度,其中头孢哌酮钠的质量是决定制剂质量的关键。
Objective To evaluate the quality of cefoperazone sodium and sulbactam sodium for injections at present. Methods All the samples were experimented according to the Chp. and other approved criteria. The data were analyzed by statistic methods. Results Seventeen samples produced by 10 pharmaceutical factories were unqualified, which were found among 54 samples produced by 30 pharmaceutical factories, with the disqualification rate of 31.5%. The major items of disqualification were solution＇s clarify and the purity of cefoperazone in all these preparations.Conclusions The solution＇s clarify and the stability of cefoperazone were the main problems for qualities of these domestic preparations, and cefoperazone sodium was the key factor for the quality of cefoperazone sodium and sulbactam sodium for injections.
出处
《药品评价》
CAS
2006年第4期282-285,共4页
Drug Evaluation
关键词
注射用头孢哌酮钠舒巴坦钠
监督抽验
质量评价
cefoperazone sodium and sulbactam sodium for injection
supervised sample
quality evaluation
